Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study

Authors
Category Primary study
JournalJournal of allergy and clinical immunology
Year 2024
This article has no abstract
Epistemonikos ID: 0a46ffa06a511b66f7a63604e879c446737ffb49
First added on: Apr 29, 2024